Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol

##STR00001##

or a pharmaceutically-acceptable salt thereof.

A delivery composition including a plurality of first nanoparticle excipients each containing an active compound pharmaceutical agent and a plurality of second nanoparticle excipients each containing a modulating agent.

The invention provides a pharmaceutical composition for dry powder inhalation and a preparation method thereof, wherein the composition comprises, a carrier material, preferably lactose and micronized remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524 and pharmaceutically acceptable salts thereof. The active pharmaceutical ingredient may be an anti-viral, taken as remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate. and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524. The dry powder inhalation containing Remdesivir and/or its active metabolites and/or its analog GS-441524 as active ingredients, further consisting of a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation deep into the lungs for the treatment of respiratory disorders. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, an active ingredient, including, small organic molecules, including, remdesivir and/or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and/or its analog GS-441524 and pharmaceutically acceptable salts thereof for the treatment of disease and disorders, for example, COVID-19 and other viral respiratory infections.

Methods and devices for coating a respiratory system and thereby protecting from or killing viral, bacterial, or viral and bacterial infections are disclosed. An active compound that is a virucide, a bactericide, or both, is vaporized by a vaporizing device and inhaled into the respiratory system where the active compound coats the respiratory system.

The present invention relates generally to the treatment of respiratory disorders. More particularly the invention is a composition and method for the treatment of respiratory disorders using inhaled norepinephrine reuptake inhibitor such as Atomoxetine.

Disclosed is inhaling or spraying sodium fluoride (NaF) or other fluoride salts, e.g., stannous fluoride, potassium fluoride, calcium fluoride, or magnesium fluoride, or other fluoride compounds, e.g., sodium monofluoro phosphate, in solution or in emulsion (carried in, e.g., a lipid phase) or where the solution or emulsion is encapsulated in microparticles into the mouth region and/or nasal cavities for treatment or prophylaxis of viral infections, including SARS-CoV-2 and other corona viruses, influenza, parainfluenza and rhinoviruses (which are the primary agents responsible for common colds) and other human and animal respiratory pathogenic viruses.

Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary disease is selected from the group consisting of Acute Respiratory Distress Syndrome, Acute Lung Injury and Acute Inflammatory Injury, and compositions thereof.

The invention provides a composition suitable for use in a personal vaporizer, comprising an oil soluble liquid emulsifier base and an extract, wherein the extract comprises a cannabinoid and a terpene, methods of administering such compositions to a subject, and related kits.

A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.